Indication: Cystic Fibrosis

A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis

Sub-indication: Cystic Fibrosis

Study Type: Drug Study

Principal Investigator: Adrian O'Hagan, M.D.
Norton Children's Pulmonology, affiliated with the UofL School of Medicine

Sponsor: Sponsor: Vertex Pharmaceuticals, Inc.

Learn more at

Email for more information:

Search our entire site.